The estimated glomerular filtration rate (eGFR) is the primary metric used to monitor kidney function and guide treatment decisions in chronic kidney disease (CKD). Glomerular Filtration Rate (GFR) represents the rate at which blood is filtered through the glomeruli, and its decline is a hallmark of CKD progression. Nephrology therapeutics are the medications designed to slow this decline, manage symptoms, and delay the need for dialysis or transplantation. The global CKD market is projected to grow from $42.87 billion in 2025 to $75.22 billion by 2035, driven by the increasing prevalence of diabetes and hypertension and the introduction of innovative therapies . For nephrologists, internists, and clinical researchers, the detailed market analysis on Nephrology Therapeutics provides essential insights.

H2: Understanding Glomerular Filtration Rate (GFR)

The Glomerular Filtration Rate (GFR) is the best overall indicator of kidney function. It represents the volume of fluid filtered by the glomeruli per unit of time. Clinically, GFR is estimated using equations based on serum creatinine, which is a waste product from muscle metabolism. The most widely recommended equation is the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula, which incorporates serum creatinine, age, sex, and race. The National Kidney Foundation (NKF) and the American Society of Nephrology (ASN) Task Force recommend using the CKD-EPI creatinine-based equation for estimated GFR (eGFR) . The Kidney Disease Improving Global Outcomes (KDIGO) guidelines classify CKD into five stages based on eGFR:

• Stage 1: GFR ≥90 mL/min/1.73 m² (normal or high)

• Stage 2: GFR 60-89 mL/min/1.73 m² (mildly decreased)

• Stage 3a: GFR 45-59 mL/min/1.73 m² (mildly to moderately decreased)

• Stage 3b: GFR 30-44 mL/min/1.73 m² (moderately to severely decreased)

• Stage 4: GFR 15-29 mL/min/1.73 m² (severely decreased)

• Stage 5: GFR <15 mL/min/1.73 m² (kidney failure) .

Monitoring eGFR trends allows clinicians to assess the rate of disease progression and the effectiveness of therapeutic interventions.

H2: Nephrology Therapeutics to Protect GFR

Nephrology Therapeutics that target the underlying causes and complications of CKD are essential for preserving GFR. RAAS inhibitors (ACE inhibitors and ARBs) have long been the mainstay of treatment for patients with CKD, particularly those with hypertension and proteinuria. They reduce intraglomerular pressure, slowing the decline in GFR . More recently, SGLT2 inhibitors have revolutionized CKD care, demonstrating significant renoprotective effects independent of glycemic control, leading to slower GFR decline and reduced risk of kidney failure . Other emerging therapies, such as GLP-1 receptor agonists and non-steroidal MRAs, are expanding the treatment options . Managing comorbidities is also crucial for preserving GFR. This includes rigorous blood pressure control (target <130/80 mmHg), glycemic control in diabetic patients, and the use of statins for dyslipidemia. Lifestyle modifications, including dietary changes (low sodium, moderate protein), smoking cessation, and weight management, are equally important pillars of nephrology therapeutics. For nephrologists and healthcare providers, the market research available on Glomerular Filtration Rate offers comprehensive guidance on integrating therapeutic strategies to protect renal function.